NCT01005472View on ClinicalTrials.gov

Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 1, 2008

Primary Completion Date

January 17, 2018

Study Completion Date

January 17, 2018

Conditions
Metastatic Melanoma
Interventions
DRUG

sunitinib malate

DRUG

temozolomide

Trial Locations (1)

90095

University of California Los Angeles (UCLA), Los Angeles

Sponsors

Collaborators (2)

Pfizer
Schering-Plough
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

Schering-Plough

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER